Clinical Trials Logo

Clinical Trial Summary

Lung cancer is the leading cause of cancer deaths,and the key to reducing mortality in lung cancer patients is early diagnosis and treatment.Currently,peripheral blood DNA methylation is a novel in vitro molecular marker for tumors.Meanwhile artificial intelligence diagnostic system can further improve the diagnostic ability.The purpose of this study is to apply the overall DNA methylation level (i.e.,methylation profile) and the altered methylation degree of specific genes as tumor diagnostic indexes,and combined with the artificial intelligence imaging technology for the early and accurate diagnosis of lung cancer,to achieve the early detection,diagnosis,and treatment of lung cancer,and to effectively reduce the mortality rate of lung cancer.


Clinical Trial Description

n/a


Study Design


NCT number NCT06220305
Study type Observational
Source The First Affiliated Hospital with Nanjing Medical University
Contact Linfu Zhou
Phone 0086-13611573618
Email linfu.zhou@126.com
Status Recruiting
Phase
Start date December 1, 2022
Completion date December 31, 2024